Newron Pharmaceuticals S.p.A. (NWPHF) Research

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions. Operating in both Italy and the United States, the company's portfolio includes Xadago (safinamide), an approved therapy for Parkinson's disease, which is also under investigation for levodopa-induced dyskinesia. Additionally, Newron is developing Evenamide for schizophrenia and its treatment-resistant form, and Ralfinamide for specific orphan indications in neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy.

Market snapshot

Symbol
NWPHF
Price
$20.00
Day change
0.00%
Market cap
$276.4M
P/E ratio
-20.00x
52-week range
9.36-20
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Adocia S.A. (ADOCY)
  • AnGes, Inc. (AMGXF)
  • NIOX Group Plc (CSSPF)
  • Dialogue Health Technologies Inc. (DLHTF)
  • Faron Pharmaceuticals Oy (FPHAF)
  • Guerbet S.A. (GUERF)
  • Hamilton Thorne Ltd. (HTLZF)
  • Opsens Inc. (OPSSF)

Open Newron Pharmaceuticals S.p.A. (NWPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.